Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

✍ Scribed by Garon, Edward B (author);Ciuleanu, Tudor-Eliade (author);Arrieta, Oscar (author);Prabhash, Kumar (author);Syrigos, Konstantinos N (author);Goksel, Tuncay (author);Park, Keunchil (author);Gorbunova, Vera (author);Kowalyszyn, Ruben Dario (author);Pikiel, Joanna (author);Czyzewicz, Grzegorz (author);Orlov, Sergey V (author);Lewanski, Conrad R (author);Thomas, Michael (author);Bidoli, Paolo (author);Dakhil, Shaker (author);Gans, Steven (author);Kim, Joo-Hang (author);Grigorescu, Alexandru (author);Karaseva, Nina (author);Reck, Martin (author);Cappuzzo, Federico (author);Alexandris, Ekaterine (author);Sashegyi, Andreas (author);Yurasov, Sergey (author);Pérol, Maurice (author)

• Book ID: 124113248
• Publisher: Elsevier BV
• Year: 2014
• Tongue: English
• Weight: 389 KB
• Volume: 384
• Category: Article
• ISSN: 0140-6736
• DOI: 10.1016/S0140-6736(14)60845-X